PDCD1 and kidney cancer: Next, we examined whether tumor-infiltrating Vδ2− γδ T cells could be associated with clinical response to PD-1 blockade by interrogating the tumor expression data in 263 patients from the IMmotion150 kidney cancer study NCT01984242 (ref. 43).